Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVI-AMG (STI-2020) for Mild to Moderate COVID-19
NCT04738175Phase 2Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Apr 2021
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of plutavimab in coronavirus disease 2019 (COVID-19), sponsored by Sorrento Therapeutics. Planned start Apr 2021; status: withdrawn.
02
Drugs
plutavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04738175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04738175.